Anti-Fungal Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User, By Distribution Channel, By Region and Competition, 2020-2030F

Description

Global Anti-Fungal Drugs Market was valued at USD 12.47 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.33% through 2030. Antifungal medications are commonly prescribed to treat fungal infections. These medications can be administered orally, topically, or intravenously via an IV drip. Fungal infections such as yeast infections, ringworm, nail and skin diseases can be caused by fungi present in the soil, air, and skin. Inhaling fungal spores may also lead to respiratory issues. Therefore, individuals with weakened immune systems are more susceptible to fungal infections, necessitating the use of antifungal medication. Most of these medications require a doctor's prescription, although a few are available over the counter.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 12.47 Billion
Market Size 2030	USD 16.11 Billion
CAGR 2025-2030	4.33%
Fastest Growing Segment	Azoles
Largest Market	North America

There are two main categories of antifungal drugs: local and systemic. Depending on the specific condition being treated, local antifungals are commonly applied topically or vaginally, while systemic antifungals are administered orally or intravenously. Examples of systemically administered medicines include itraconazole, fluconazole, ketoconazole, voriconazole, posaconazole, and isavuconazole. Antifungal medications can function in one of two ways: they can directly kill fungal cells or inhibit their growth and development. Moreover, antifungal medications work by targeting structures or functions that are essential in fungal cells but not in human cells, allowing them to combat fungal infections without harming human cells. The fungal cell membrane and cell wall are frequently targeted components, as they surround and protect the fungal cell. Compromising either of these structures can cause the fungal cell to burst open and die.

Key Market Drivers

Rising Prevalence of Fungal Infections

The increasing prevalence of fungal infections is a key driver for the revenue growth in the market. Research indicates that fungal pathogens are responsible for approximately 13 million infections and 1.5 million deaths worldwide each year. Antifungal medications are also administered orally. On March 30, 2023, GSK plc and SCYNEXIS, Inc. announced an exclusive license agreement for Brexafemme, a first-in-class antifungal approved by the U.S. Food and Drug Administration (FDA) for the treatment of Vulvovaginal Candidiasis (VVC) and the reduction of the incidence of recurrent VVC (RVVC). This exclusive licensing deal grants GSK the sole right to commercialize Brexafemme for VVC and RVVC while continuing the development of ibrexafungerp, which is currently in phase III clinical trials for the possible treatment of Invasive Candidiasis (IC), a potentially fatal fungal infection.

The prevalence of fungal infections has been on the rise in recent years, prompting concerns within the healthcare industry. Contributing factors to this alarming trend include increasing global temperatures, the prevalence of chronic illnesses, and compromised immune systems. Hospital-acquired fungal infections, or nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, according to the Centers for Disease Control and Prevention (CDC).

Key Market Challenges

Adverse Health Effects

There are several disadvantages associated with antifungal drugs. One key factor is that individuals with weakened immune systems, such as those with acquired immunodeficiency syndrome (AIDS), lupus, cancer, and other conditions, are more susceptible to dangerous fungal infections known as opportunistic infections. This vulnerability poses a challenge to the revenue growth of the antifungal drug market.

Furthermore, the type of medicine, dosage strength, and the specific fungus being treated can all influence the outcome of the medication. Common side effects may include pain in the abdomen, unsettled stomach, diarrhea, and itchy, scorching, or rashy skin. These symptoms can also have a negative impact on the revenue growth of the market.

In addition to these challenges, antifungal medication can produce major side effects, including liver damage such as jaundice, anaphylaxis, and other severe allergic responses. Blisters and peeling skin are also symptoms of severe allergic skin reactions that can occur as a result of using antifungal drugs. Considering these factors, it becomes evident that while antifungal drugs are necessary for treating fungal infections, they do come with significant drawbacks that need to be taken into account.

Key Market Trends

Increase In the Number of Research and Development Activities

The increase in the number of research and development (R&D) activities in the field of antifungal drugs is expected to significantly boost the demand for these medications. Antifungal drugs are critical for treating a wide range of fungal infections, from superficial conditions like athlete's foot to life-threatening systemic infections. Increasing R&D investments lead to the discovery of new antifungal compounds and formulations. These innovations are likely to result in the development of more effective drugs with improved mechanisms of action, enhancing the arsenal of treatment options available. R&D efforts are dedicated to understanding and combating antifungal resistance. Researchers are working to identify the mechanisms behind resistance and develop strategies to overcome it. This will ensure the continued effectiveness of antifungal drugs, driving their demand. Research in the field of fungal biology is uncovering specific molecular targets within fungal cells that can be exploited for drug development. Targeted therapies can enhance drug efficacy and reduce side effects, making antifungal drugs more appealing to healthcare providers and patients.

Key Market Players

Abbott Laboratories Inc.
Astellas Pharma Inc.
Bayer AG
GSK plc
Glenmark Pharmaceuticals Limited
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Mycovia Pharmaceuticals, Inc.
Apex Laboratories Pvt. Ltd.

Report Scope:

In this report, the Global Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Fungal Drugs Market, By Drug Class:

Azoles
Echinocandins
Polyenes
Allylamines
Others

Anti-Fungal Drugs Market, By Indication:

Candidiasis
Aspergillosis
Mucormycosis
Dermatophytosis
Others

Anti-Fungal Drugs Market, By Infection Type:

Superficial Fungal Infection
Systemic Fungal Infection

Anti-Fungal Drugs Market, By Route of Administration:

Topical
Oral
Parenteral
Others

Anti-Fungal Drugs Market, By End User:

Homecare
Hospitals
Clinics
Others

Anti-Fungal Drugs Market, By Distribution Channel:

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

Anti-Fungal Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Fungal Drugs Market.

Available Customizations:

Global Anti-Fungal Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Fungal Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
- 5.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
- 5.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
- 5.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
- 5.2.5. By End User (Homecare, Hospitals, Clinics, Others)
- 5.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
- 5.2.7. By Region
- 5.2.8. By Company (2024)
5.3. Market Map

6. North America Anti-Fungal Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Indication
- 6.2.3. By Infection Type
- 6.2.4. By Route Of Administration
- 6.2.5. By End User
- 6.2.6. By Distribution Channel
- 6.2.7. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anti-Fungal Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By Infection Type
    - 6.3.1.2.4. By Route Of Administration
    - 6.3.1.2.5. By End User
    - 6.3.1.2.6. By Distribution Channel
- 6.3.2. Canada Anti-Fungal Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By Infection Type
    - 6.3.2.2.4. By Route Of Administration
    - 6.3.2.2.5. By End User
    - 6.3.2.2.6. By Distribution Channel
- 6.3.3. Mexico Anti-Fungal Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By Infection Type
    - 6.3.3.2.4. By Route Of Administration
    - 6.3.3.2.5. By End User
    - 6.3.3.2.6. By Distribution Channel

7. Europe Anti-Fungal Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Indication
- 7.2.3. By Infection Type
- 7.2.4. By Route Of Administration
- 7.2.5. By End User
- 7.2.6. By Distribution Channel
- 7.2.7. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anti-Fungal Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By Infection Type
    - 7.3.1.2.4. By Route Of Administration
    - 7.3.1.2.5. By End User
    - 7.3.1.2.6. By Distribution Channel
- 7.3.2. United Kingdom Anti-Fungal Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By Infection Type
    - 7.3.2.2.4. By Route Of Administration
    - 7.3.2.2.5. By End User
    - 7.3.2.2.6. By Distribution Channel
- 7.3.3. Italy Anti-Fungal Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By Infection Type
    - 7.3.3.2.4. By Route Of Administration
    - 7.3.3.2.5. By End User
    - 7.3.3.2.6. By Distribution Channel
- 7.3.4. France Anti-Fungal Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By Infection Type
    - 7.3.4.2.4. By Route Of Administration
    - 7.3.4.2.5. By End User
    - 7.3.4.2.6. By Distribution Channel
- 7.3.5. Spain Anti-Fungal Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By Infection Type
    - 7.3.5.2.4. By Route Of Administration
    - 7.3.5.2.5. By End User
    - 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Anti-Fungal Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Indication
- 8.2.3. By Infection Type
- 8.2.4. By Route Of Administration
- 8.2.5. By End User
- 8.2.6. By Distribution Channel
- 8.2.7. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Anti-Fungal Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By Infection Type
    - 8.3.1.2.4. By Route Of Administration
    - 8.3.1.2.5. By End User
    - 8.3.1.2.6. By Distribution Channel
- 8.3.2. India Anti-Fungal Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By Infection Type
    - 8.3.2.2.4. By Route Of Administration
    - 8.3.2.2.5. By End User
    - 8.3.2.2.6. By Distribution Channel
- 8.3.3. Japan Anti-Fungal Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By Infection Type
    - 8.3.3.2.4. By Route Of Administration
    - 8.3.3.2.5. By End User
    - 8.3.3.2.6. By Distribution Channel
- 8.3.4. South Korea Anti-Fungal Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By Infection Type
    - 8.3.4.2.4. By Route Of Administration
    - 8.3.4.2.5. By End User
    - 8.3.4.2.6. By Distribution Channel
- 8.3.5. Australia Anti-Fungal Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Infection Type
    - 8.3.5.2.4. By Route Of Administration
    - 8.3.5.2.5. By End User
    - 8.3.5.2.6. By Distribution Channel

9. South America Anti-Fungal Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Indication
- 9.2.3. By Infection Type
- 9.2.4. By Route Of Administration
- 9.2.5. By End User
- 9.2.6. By Distribution Channel
- 9.2.7. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Anti-Fungal Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By Infection Type
    - 9.3.1.2.4. By Route Of Administration
    - 9.3.1.2.5. By End User
    - 9.3.1.2.6. By Distribution Channel
- 9.3.2. Argentina Anti-Fungal Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By Infection Type
    - 9.3.2.2.4. By Route Of Administration
    - 9.3.2.2.5. By End User
    - 9.3.2.2.6. By Distribution Channel
- 9.3.3. Colombia Anti-Fungal Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By Infection Type
    - 9.3.3.2.4. By Route Of Administration
    - 9.3.3.2.5. By End User
    - 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Anti-Fungal Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Indication
- 10.2.3. By Infection Type
- 10.2.4. By Route Of Administration
- 10.2.5. By End User
- 10.2.6. By Distribution Channel
- 10.2.7. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Anti-Fungal Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By Infection Type
    - 10.3.1.2.4. By Route Of Administration
    - 10.3.1.2.5. By End User
    - 10.3.1.2.6. By Distribution Channel
- 10.3.2. Saudi Arabia Anti-Fungal Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By Infection Type
    - 10.3.2.2.4. By Route Of Administration
    - 10.3.2.2.5. By End User
    - 10.3.2.2.6. By Distribution Channel
- 10.3.3. UAE Anti-Fungal Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By Infection Type
    - 10.3.3.2.4. By Route Of Administration
    - 10.3.3.2.5. By End User
    - 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Anti-Fungal Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Abbott Laboratories Inc.
- 15.1.1. Business Overview
- 15.1.2. Service Offerings
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Astellas Pharma Inc.
15.3. Bayer AG
15.4. GSK plc
15.5. Glenmark Pharmaceuticals Limited
15.6. Merck & Co. Inc.
15.7. Novartis AG
15.8. Pfizer Inc.
15.9. Mycovia Pharmaceuticals, Inc.
15.10. Apex Laboratories Pvt. Ltd.